Metabolic & Cardiometabolic
statins worsens skeletal-muscle mitochondrial function and CoQ10 status, contributing to myalgia
In plain terms: Do statins damage muscle energy machinery (mitochondria/CoQ10) and cause the muscle aches people report?
Contested Metabolic & Cardiometabolic 🔬 Includes disconfirming
Part of: 💊 statins
RefutedContestedStrong support
consensus score -0.19
Statins measurably lower muscle mitochondrial respiration, but CoQ10 depletion is inconsistent and blinded trials show most reported muscle aches are not actually caused by the drug.
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Human trials (RCT / n-of-1)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
3 support 3 contradict 2 tested null 4 mixed · 12 sources, 6 independent groups
What the evidence shows
Contested, because the claim joins two findings that go different ways. On the mitochondrial half, small non-randomised human studies split: statin users showed lower muscle CoQ10 and reduced maximal respiration in one study of 19 people, and complex III inhibition in surgical muscle samples, but a 2-week before-after study and the larger LIFESTAT comparison found CoQ10 and maximal respiratory…
The evidence (15)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Hussain A, Kaler J, Ray SD 2023 · Cureus | mechanism | supports | low | Narrative review: 'this review has focused on the mechanistic and clinical aspects of this statin class of medication'; states 'The impairment of mitochondrial function is another adverse effect' and that pathophysiology 'is still not fully understood'. Review — zero weight. |
| Wood FA, Howard JP, Finegold JA, Nowbar AN, Thompson DM, Arnold AD, Rajkumar CA, Connolly S, Cegla J, Stride C, Sever P, Norton C, Thom SAM, Shun-Shin MJ, Francis DP 2020 · N Engl J Med | RCT | contradicts | high | N-of-1 crossover: 90% of statin-attributed symptom burden occurred equally on placebo; muscle symptoms largely nocebo, not pharmacological |
| Dohlmann TL, Kuhlman AB, Morville T, Dahl M, Asping M, Orlando P, Silvestri S, Tiano L, Helge JW, Dela F, Larsen S 2022 · Antioxidants (Basel) | observational | contradicts | moderate | LIFESTAT sub-study: '37 men and women in simvastatin therapy with and without myalgia were randomized to receive 400 mg CoQ10 daily or matched placebo tablets for eight weeks.' Statin exposure was NOT randomised (all on simvastatin, no statin-free arm), so graded observational on this claim (§5 addendum 3). 'CoQ10 supplementation had no effect on muscle CoQ10 levels or mitochondrial function and did not affect symptoms of myalgia'; muscle CoQ10 changes did not correlate with myalgia change (r = 0.0136; p = 0.948). Authors: it 'adds doubt ... to whether the mechanism underlying statin-induced myalgia involves reduced muscle CoQ10 levels and impaired mitochondrial function'. Caveat: supplementation never raised muscle CoQ10, and only none-to-moderate myalgia was studied. |
| Herrett E, Williamson E, Brack K, Perkins A, Thayne A, Shakur-Still H, Roberts I, Prowse D, Beaumont D, Jamal Z, Goldacre B, van Staa T, MacDonald TM, Armitage J, Moore M, Hoffman M, Smeeth L 2021 · Health Technol Assess | RCT | contradicts | high | Series of 200 double-blind N-of-1 RCTs (atorvastatin 20 mg vs placebo, six 2-month periods; 151 analysed) in patients who stopped or were considering stopping statins over muscle symptoms: 'There was no evidence of a difference in muscle symptom scores between statin and placebo periods (mean difference statin minus placebo –0.11, 95% confidence interval –0.36 to 0.14; p = 0.398).' Caveat: withdrawals for intolerable symptoms were more common in statin periods, 'we cannot exclude the possibility that a minority of patients may experience muscle symptoms caused by their statin.' Measures myalgia only - no mitochondrial or CoQ10 endpoint (bears on the claim's myalgia clause). |
| Cholesterol Treatment Trialists' Collaboration 2022 · Lancet | meta-analysis | mixed | high | IPD of blinded RCTs: real but small excess of muscle pain/weakness (~11 events/1000 person-yr, RR 1.03 first year); >90% of reported symptoms not statin-caused |
| Mollazadeh H, Tavana E, Fanni G, Bo S, Banach M, Pirro M, von Haehling S, Jamialahmadi T, Sahebkar A 2021 · J Cachexia Sarcopenia Muscle | mechanism | supports | low | Mechanistic narrative review: 'In this review, we aim to report the mechanisms of action of statins on mitochondrial function'; lists CoQ10 reduction, respiratory-chain inhibition, mitochondrial apoptosis. No new data or pooling — review, zero weight. |
| Asping M, Stride N, Søgaard D, Dohlmann TL, Helge JW, Dela F, Larsen S 2017 · Eur J Clin Pharmacol | observational | tested-null | moderate | Asping 2017 LIFESTAT, healthy middle-aged men, 2 weeks simvastatin (n=10) or pravastatin (n=10), pre vs post (no statin-free comparator reported, so graded observational): 'No differences were seen in mitochondrial respiratory capacity' and 'No differences were seen in Q10, CS activity, or antioxidant content after treatment'; complex IV respiration only a tendency (S 229 vs 179 pmol/s/mg, P = 0.062; P 214 vs 162, P = 0.053). Null on the object = contradicts; short and small. [abstract-grade] Underpowered trend toward the claim (point estimate favours it, interval includes no effect): graded tested-null per CONVENTIONS §5 second clarification 2026-09-26. |
| Dohlmann TL, Morville T, Kuhlman AB, Chrøis KM, Helge JW, Dela F, Larsen S 2019 · J Clin Endocrinol Metab | observational | mixed | moderate | Cross-sectional comparison within LIFESTAT (statin exposure NOT randomised): 64 simvastatin users (25 myalgic, 39 symptom-free) vs 20 untreated hypercholesterolaemic controls. 'Intramuscular CoQ10 concentration was comparable among groups. Mitochondrial complex II-linked respiration was reduced in the statin-myalgic and -NS groups compared with the control group', but 'the mitochondrial capacity for complex I+II-linked respiration remained intact' and 'Myalgia was not coupled to reduced intramuscular CoQ10 levels'; CS-normalised respiration was HIGHER in the myalgic group. Two-way on the object (complex II down; CoQ10, maximal capacity and the myalgia link against). Graded observational: randomisation was not of statin vs no statin. [abstract-grade; no effect sizes or p values in the abstract] |
| El-Ganainy SO, El-Mallah A, Abdallah D, Khattab MM, Mohy El-Din MM, El-Khatib AS 2016 · Toxicology | animal | supports | low | In rats atorvastatin caused mitochondrial swelling, ATP depletion and myopathy that CoQ10 co-treatment reversed, supporting a mitochondrial mechanism. |
| Kovacic S, Habicht SD, Eckert GP 2025 · J Nutr Sci | meta-analysis | mixed | low | 7 RCTs n=389: modest overall reduction in SAMS pain with CoQ10 (WMD -0.96) but 3/7 trials null; heterogeneous, low-certainty benefit |
| Larsen S, Stride N, Hey-Mogensen M, Hansen CN, Bang LE, Bundgaard H, Nielsen LB, Helge JW, Dela F 2013 · J Am Coll Cardiol | observational | supports | moderate | Cross-sectional, simvastatin-treated patients (n=10) vs matched controls (n=9): 'Q(10) content was reduced (p = 0.05), whereas mitochondrial content was similar'; OXPHOS 'comparable between groups when complex I- and complex II-linked substrates were used alone', but with complex I+II substrates (maximal ex vivo OXPHOS capacity) 'a decreased (p < 0.01) capacity was observed in the patients'. Myalgia was not measured; the authors call the link to muscle pain 'plausible'. [abstract-grade; n=19] |
| Golomb BA, Han JH, Langsjoen PH, Dinkeloo E, Zemljic-Harpf AE 2023 · J Clin Med | observational | supports | low | Review argues statins impair mitochondrial function in those most reliant on CoQ10 (a mevalonate pathway product transported on cholesterol), amplifying risk in patients with existing mitochondrial compromise; argument made in context of CO |
| Peyrel P, Mauriège P, Frenette J, Laflamme N, Greffard K, Dufresne SS, Huth C, Bergeron J, Joanisse DR 2023 · PLoS One | observational | mixed | low | In patients reporting statin muscle symptoms, drug withdrawal improved perceived but not objective muscle function, implicating a nocebo rather than true mitochondrial injury for the reported aches. |
| Braczko A, Harasim G, Kawecka A, Walczak I, Kapusta M, Narajczyk M, Stawarska K, Smoleński RT, Kutryb-Zając B 2023 · Front Physiol | in-vitro | tested-null | low | In mouse heart microvascular endothelial cells and cardiomyocytes under normal conditions, atorvastatin (unlike a PCSK9 inhibitor) did not enhance mitochondrial respiratory parameters, but under hypoxia-mimicking conditions atorvastatin act |
| Somers T, Siddiqi S, Janssen MCM, Morshuis WJ, Maas RGC, Buikema JW, van den Broek PHH, Schirris TJJ, Russel FGM 2024 · Biomed Pharmacother | observational | supports | high | Ex vivo tissue from cardiac-surgery patients taking atorvastatin, rosuvastatin, simvastatin or pravastatin vs patients without statins (not randomised). On the claim's object (skeletal muscle): 'Inhibition of mitochondrial complex III by statins, as previously described, was confirmed in skeletal muscle when compared to control samples'. Cardiac findings (reduced FAO and complex I/II activity, contractility unaffected) are off-object. Abstract gives no n, effect sizes or p values; CoQ10 and myalgia not measured. [abstract-grade] |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.